THERAMetrics and Centurion Pharma collaboration in rare diseases area
Switzerland’s THERAMetrics holding (SIX: TMX) and Turkish drugmaker Centurion Pharma plan to cooperate in the development and registration of aviptadil for the treatment of cystic fibrosis and sarcoidosis, and interferon gamma for the treatment of idiopathic pulmonary fibrosis.
Under the proposed terms, this collaboration is initially for Turkey and eventually in other neighboring markets. THERAMetrics is the patent holder on both products in the given indications and has adopted Orphan Medicinal Product Designations in the USA and Europe. The parties have committed to sign definitive agreements by December 2014.
Orphan diseases a $9 billion market in Turkey
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze